Table I.
Comparisons of general features and clinical manifestation between different groups.
| P-value | |||||||
|---|---|---|---|---|---|---|---|
| Item | MOG antibody (+) | AQP4 antibody (+) | MOG/AQP4 antibody (−) | MOG/AQP4 antibody (+) | MOG antibody (+) vs. AQP4 antibody (+) | MOG antibody (+) vs. MOG/AQP4 antibody (−) | AQP4 antibody (+) vs. MOG/AQP4 antibody (−) |
| Cases (n) | 11 | 20 | 11 | 1 | |||
| Sex (male/female) | 4/7 | 1/19 | 6/5 | 0/1 | 0.041 | 0.691 | 0.005 |
| Age at onset (years) | 31.55±13.03 | 33.65±11.29 | 32.55±12.17 | 28 | 0.386 | 0.963 | 0.442 |
| Median course of disease (months) | 24 | 30 | 12 | 156 | 0.531 | 0.158 | 0.334 |
| Eye pain n (%) | 7 (63.6%) | 13 (65%) | 7 (63.6%) | 0 (0%) | 1.000 | 1.000 | 1.000 |
| Optic disk edema (n) | 5 (45.5%) | 4 (20%) | 8 (72.3%) | 0 (0%) | 0.228 | 0.369 | 0.006 |
| Median onset frequency (time) | 2 | 3 | 2 | 5 | 0.224 | 0.273 | 0.006 |
| Maximum VFSS score prior to treatment | 5 | 6 | 5 | 5 | 0.009 | 0.164 | 0.055 |
| Maximum VFSS score at 6 months after treatment | 1 | 3 | 1 | 3 | 0.001 | 0.053 | 0.014 |
| Affected eyes n (%) | 20 (90.1%) | 39 (97.5%) | 22 (100%) | 2 (100%) | |||
| Vision ≤0.1 at onset n (%) | 10 (45.5%) | 33 (82.5%) | 13 (59.1) | 1 (50%) | 0.013 | 0.733 | 0.034 |
| Vision ≤0.1 after treatment n (%) | 2 (9.1%) | 20 (50%) | 2 (9.1%) | 0 (0%) | 0.002 | 1.000 | 0.001 |
MOG, myelin oligodendrocyte glycoprotein; AQP, aquaporin; VFSS, videofluoroscopic swallowing study.